A combined DTaP-IPV vaccine (Tetraxim®/Tetravac®) used as school-entry booster: a review of more than 20 years of clinical and post-marketing experience

References

• Henderson RH. The expanded programme on immunization of the World Health Organization. Rev Infect Dis. 1984 May-Jun;6(Suppl 2):S475–9.
   PubMedGoogle Scholar
• WHO. Immunization and vaccine-preventable diseases. [cited 2022 May 4]. Available from: https://www.who.int/data/gho/data/themes/immunization
   Google Scholar
• WHO. Polio (Pol3) immunization coverage amonth 1-year-olds (%). [cited 2022 May 4]. Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/polio-(pol3)-immunization-coverage-among-1-year-olds-(-)
   Google Scholar
• Cohen R, Ashman M, Taha MK, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021 Aug;51(5):418–423.
   PubMedGoogle Scholar
• Moura C, Truche P, Sousa Salgado L, et al. The impact of COVID-19 on routine pediatric vaccination delivery in Brazil. Vaccine. 2022 Apr 1 40(15):2292–2298.
   PubMed Web of Science ®Google Scholar
• Patel Murthy B, Zell E, Kirtland K, et al. Impact of the COVID-19 pandemic on administration of selected routine childhood and adolescent vaccinations - 10 U.S. Jurisdictions, March-September 2020. Morbidity Mortality Weekly Rep. 2021 Jun 11 70(23):840–845.
   PubMed Web of Science ®Google Scholar
• SeyedAlinaghi S, Karimi A, Mojdeganlou H, et al. Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: a systematic review. Health Sci Rep. 2022 Mar;5(2):e00516.
   PubMedGoogle Scholar
• WHO. Diphtheria reported cases. Available from: https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencediphtheria.html. Accessed 4 May 2022.
   Google Scholar
• WHO. Review of the epidemiology of diphtheria - 2000-2016. Available from: https://www.who.int/immunization/sage/meetings/2017/april/1_Final_report_Clarke_april3.pdf. Accessed 4 May 2022.
   Google Scholar
• Clarke KEN, MacNeil A, Hadler S, et al. Global epidemiology of Diphtheria, 2000-2017. Emerg Infect Dis. 2019 Oct;25(10):1834–1842.
   PubMed Web of Science ®Google Scholar
• Finger F, Funk S, White K, et al. Real-time analysis of the diphtheria outbreak in forcibly displaced Myanmar nationals in Bangladesh. BMC Med. 2019 Mar 12 17(1):58.
   PubMedGoogle Scholar
• Karyanti MR, Nelwan EJ, Assyidiqie IZ, et al. Diphtheria epidemiology in Indonesia during 2010-2017. Acta Med Indones. 2019 Jul;51(3):205–213.
   PubMed Web of Science ®Google Scholar
• Polonsky JA, Ivey M, Mazhar MKA, et al. Epidemiological, clinical, and public health response characteristics of a large outbreak of diphtheria among the Rohingya population in Cox’s Bazar, Bangladesh, 2017 to 2019: a retrospective study. PLoS Med. 2021 Apr;18(4):e1003587.
   PubMed Web of Science ®Google Scholar
• Sangal L, Joshi S, Anandan S, et al. Resurgence of diphtheria in North Kerala, India, 2016: laboratory supported case-based surveillance outcomes. Front Public Health. 2017;5:218.
   PubMed Web of Science ®Google Scholar
• Paniz-Mondolfi AE, Tami A, Grillet ME, et al. Resurgence of vaccine-preventable diseases in Venezuela as a regional public health threat in the Americas. Emerg Infect Dis. 2019 Apr;25(4):625–632.
   PubMed Web of Science ®Google Scholar
• WHO.Diphtheria vaccine: WHO position paper.August 2017;Weekly Epidemiological Rec. 2017 Aug 4 9231 417–435.
   PubMedGoogle Scholar
• Roper M, Wassilak S, Scobie H. Tetanus toxoid. Plotkin SA, Orenstein WA, Offit PA, et al., editors. Vaccines. 7th ed. PA:Elsevier; 2018. p.1052–1079.
   Google Scholar
• WHO. Tetanus vaccines: WHO position paper - February 2017. Weekly Epidemiological Rec. 2017 Feb 10;92(6):53–76.
   PubMedGoogle Scholar
• Borrow R, Balmer P, Roper M The Immunological Basis for Immunization Series—Module 3: tetanus Update 2018. Immunization, Vaccines and Biologicals, WHO Edition World Health Organization, Geneva. 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/275340/9789241513616-eng.pdf?sequence=1&isAllowed=y. Accessed 4 May 2022. Accessed 4 May 2022.
   Google Scholar
• WHO. Pertussis vaccines: WHO position paper - September 2015. Weekly Epidemiological Rec. 2015 Aug 28;90(35):433–458.
   PubMedGoogle Scholar
• Falleiros Arlant LH, de Colsa A, Flores D, et al. Pertussis in Latin America: epidemiology and control strategies. Expert Rev Anti Infect Ther. 2014 Oct;12(10):1265–1275.
   PubMed Web of Science ®Google Scholar
• Gambhir M, Clark TA, Cauchemez S, et al. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. PLoS Comput Biol. 2015 Apr;11(4):e1004138.
   PubMed Web of Science ®Google Scholar
• Gentile A, Bricks L, Avila-Aguero ML, et al. Pertussis in Latin America and the Hispanic Caribbean: a systematic review. Expert Rev Vaccines. 2019 Aug;18(8):829–845.
   PubMed Web of Science ®Google Scholar
• Huang H, Gao P, Gao Z, et al. A big pertussis outbreak in a primary school with high vaccination coverage in northern China: an evidence of the emerging of the disease in China. Vaccine. 2018 Dec 18 36(52):7950–7955.
   PubMed Web of Science ®Google Scholar
• van der Maas Na, Mooi FR, de Greeff Sc, et al. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine. 2013 Sep 23 31(41):4541–4547.
   PubMed Web of Science ®Google Scholar
• Worby CJ, Kenyon C, Lynfield R, et al. Examining the role of different age groups, and of vaccination during the 2012 Minnesota pertussis outbreak. Sci Rep. 2015 Aug 17 5(1):13182.
   PubMedGoogle Scholar
• Pillsbury A, Quinn HE, McIntyre PB. Australian vaccine preventable disease epidemiological review series: pertussis, 2006-2012. Commun Dis Intell Q Rep. 2014 Sep 30;38(3):E179–94.
   PubMedGoogle Scholar
• de Greeff Sc, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clinl Infect Dis. 2010 May 15 50(10):1339–1345.
   PubMed Web of Science ®Google Scholar
• de Celles M D, Magpantay FMG, King AA, et al. The impact of past vaccination coverage and immunity on pertussis resurgence. Sci Transl Med. 2018 Mar 28;10(434):eaaj1748. doi:10.1126/scitranslmed.aaj1748.
   PubMed Web of Science ®Google Scholar
• Jardine A, Conaty SJ, Lowbridge C, et al., Who gives pertussis to infants? Source of infection for laboratory confirmed cases less than 12 months of age during an epidemic. Commun Dis Intell Q Rep. 2009;34(2): 116–121. 2010 Jun. Sydney
   Google Scholar
• Skoff TH, Kenyon C, Cocoros N, et al. Sources of infant pertussis infection in the United States. Pediatrics. 2015 Oct;136(4):635–641.
   PubMed Web of Science ®Google Scholar
• The Public Health Agency of Sweden. Pertussis surveillance in Sweden: twenty-year report. Available from: https://www.folkhalsomyndigheten.se/contentassets/14d7068f02604bb496a319895fd9ad47/pertussis-sweden-twenty-year-report-18068.pdf. Accessed 4 May 2022.
   Google Scholar
• de Greeff Sc, Mooi FR, Schellekens JFP, et al. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J. 2008 Mar;27(3):218–223.
   PubMed Web of Science ®Google Scholar
• Domenech de Celles M, Rohani P, King AA. Duration of immunity and effectiveness of diphtheria-tetanus-acellular pertussis vaccines in children. JAMA Pediatr. 2019 Jun 1; 173(6):588–594.
   PubMed Web of Science ®Google Scholar
• Global Polio Eradication Initiative. Available from: https://polioeradication.org/. Accessed 4 May 2022.
   Google Scholar
• Global Polio Eradication Initiative. Global wild poliovirus 2016-2021. Available from: https://polioeradication.org/wp-content/uploads/2021/09/Weekly-GPEI-Polio-Analyses-WPV-20210831.pdf. Accessed 4 May 2022.
   Google Scholar
• Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus. Available from: https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/. Accessed 4 May 2022.
   Google Scholar
• WHO. Polio vaccines: WHO position paper. Weekly Epidemiological Rec. 2016 March;91(12):145–168.
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control. Vaccine schedules in all countries in the EU/EEA. Available from: https://vaccine-schedule.ecdc.europa.eu/. Accessed 4 May 2022.
   Google Scholar
• Centers for Disease Control. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States. Available from: https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed 4 May 2022.
   Google Scholar
• Government of Canada. Recommended immunization schedules: canadian Immunization Guide. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-13-recommended-immunization-schedules.html. Accessed 4 May 2022.
   Google Scholar
• Australian Government Department of Health. National Immunisation Program Schedule – from 1 July 2020. Available from: https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#national-immunisation-program-schedule-from-1-july-2020. Accessed 4 May 2022.
   Google Scholar
• Nicholson N, Adkins E, Karyanti MR, et al. What is the true burden of diphtheria, tetanus, pertussis and poliovirus in children aged 3–18 in Asia? A systematic literature review. Inter J Infect Dis. 2022;117:116–129.
   PubMed Web of Science ®Google Scholar
• Argentina Ministry of Health. National vaccination calendar: information about vaccines and the vaccination schedule. Available from: https://www.argentina.gob.ar/salud/vacunas. Accessed 4 May 2022.
   Google Scholar
• Ministerio de Salud de Costa Rica. Esquema de vacunaciόn oficial en Costa Rica. Available from: https://www.ministeriodesalud.go.cr/index.php/centro-de-informacion/material-comunicacion/vacunas-3/5351-esquema-de-vacunacion-oficial-en-costa-rica-menores-de-edad/file. Accessed 4 May 2022.
   Google Scholar
• McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim®): a review of its use in primary and booster vaccination. Paediatr Drugs. 2013 Feb;15(1):59–70.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Liese J, Madhi SA, et al. A DTaP-IPV//PRP~T vaccine (Pentaxim): a review of 16 years’ clinical experience. Expert Rev Vaccines. 2011 Jul;10(7):981–1005.
   PubMed Web of Science ®Google Scholar
• Syed YY. DTaP-IPV-HepB-Hib vaccine (Hexyon®): an updated review of its use in primary and booster vaccination. Paediatr Drugs. 2019 Oct;21(5):397–408.
   PubMed Web of Science ®Google Scholar
• Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum Vaccines. 2008 Sep-Oct;4(5):328–340.
   PubMed Web of Science ®Google Scholar
• Auerbach BS, Lake AM, Wilson ME, et al. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine. Biologicals. 1998 Jun;26(2):145–153.
   PubMed Web of Science ®Google Scholar
• Edwards KM, Decker MD, Halsey NA, et al. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics. 1991 Nov;88(5):1019–1023.
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM. The multicenter acellular pertussis trial: an overview. J Infect Dis. 1996 Nov;174(Suppl 3):S270–5.
   PubMedGoogle Scholar
• Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995 Sep;96(3 Pt 2):557–566.
   PubMed Web of Science ®Google Scholar
• Miller E, Ashworth LA, Redhead K, et al. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine. 1997 Jan;15(1):51–60.
   PubMed Web of Science ®Google Scholar
• Simondon F, Yam A, Gagnepain JY, et al. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants. Eur J Clin Microbiol Infect Dis. 1996 Dec;15(12):927–932.
   PubMed Web of Science ®Google Scholar
• Simondon F, Preziosi M-P, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 1997 Oct;15(15):1606–1612.
   PubMed Web of Science ®Google Scholar
• Decker M, Edwards K, Bogaerts H. Combination vaccines. In: Plotkin SA, Orenstein WA, Offit PA, et al., editors. Vaccines. 7th ed. PA: Elsevier; 2018. p. 198–227.
   Google Scholar
• Maman K, Zollner Y, Greco D, et al. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132–2141.
   PubMed Web of Science ®Google Scholar
• Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007 Jun;26(6):496–500.
   PubMed Web of Science ®Google Scholar
• Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J. 2001 Nov;20(11 Suppl):S10–8.
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Verstraeten T, et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006 Jun;25(6):507–512.
   PubMed Web of Science ®Google Scholar
• Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003 Jan;9(1 Suppl):S6–12.
   PubMed Web of Science ®Google Scholar
• Institute for Safe Medication Practices (ISMP). Recommendations for practitioners to prevent vaccine errors part 2: analysis of ISMP vaccine errors reporting program (ISMP VERP) 2015. Available from: https://www.ismp.org/resources/recommendations-practitioners-prevent-vaccine-errors-part-2-analysis-ismp-vaccine-errors. Accessed 4 May 2022.
   Google Scholar
• Langue J, Matisse N, Pacoret P, et al. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine. 2004 Mar 29 22(11–12):1406–1414.
   PubMed Web of Science ®Google Scholar
• Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, et al. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children. Southeast Asian J Trop Med Public Health. 2012 May;43(3):687–698.
   PubMed Web of Science ®Google Scholar
• Mallet E, Matisse N, Mathieu N, et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine. 2004 Mar 29 22(11–12):1415–1422.
   PubMed Web of Science ®Google Scholar
• Collins CL, Salt P, McCarthy N, et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine. 2004 Oct 22 22(31–32):4262–4269.
   PubMed Web of Science ®Google Scholar
• John T, Voysey M, Yu LM, et al. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: a 5-year follow-up of a randomised controlled study. Vaccine. 2015 Aug 26 33(36):4579–4585.
   PubMed Web of Science ®Google Scholar
• Ferrera G, Cuccia M, Mereu G, et al. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy. Hum Vaccin Immunother. 2012 Mar;8(3):355–362.
   PubMed Web of Science ®Google Scholar
• Scheifele D, Ochnio J The immunological basis for immunization series—Module 2: diphtheria Update 2009: immunization, Vaccines and Biologicals, WHO Edition World Health Organization, Geneva. 2009. Available from: https://apps.who.int/iris/bitstream/handle/10665/44094/9789241597869_eng.pdf?sequence=1&isAllowed=y. Accessed 4 May 2022.
   Google Scholar
• Tiwari T, Wharton M. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, Offit PA, et al., editors. Vaccines. 7th ed. PA: Elsevier; 2018. p. 261–275.
   Google Scholar
• Lynn F, Reed GF, Meade BD. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin Diagn Lab Immunol. 1996 Nov;3(6):689–700.
   PubMedGoogle Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccin Immunol. 2010 Jul;17(7):1055–1065.
   PubMed Web of Science ®Google Scholar
• Wirsing von Konig C The immunological basis for immunization series—Module 4: pertussis. immunization, vaccines and biologicals, WHO Edition World Health Organization, Geneva. 2009. Available from: http://apps.who.int/iris/bitstream/handle/10665/44311/9789241599337_eng.pdf?sequence=1. Accessed 4 May 2022.
   Google Scholar
• Vidor E, Orenstein WA. Poliovirus vaccine. In: Plotkin SA, Orenstein WA, Offit PA, et al., editors. Vaccines. 7th ed. PA: Elsevier; 2018. p. 841–865.
   Google Scholar
• Robertson S The immunological basis for immunization series—Module 6: poliomyelitis. immunization, vaccines and biologicals, WHO Edition World Health Organization, Geneva 1993. WHO/EPI/GEN/93.16. Available from: https://www.who.int/ihr/polio1993en.pdf. Accessed 4 May 2022.
   Google Scholar
• Albrecht P, Enterline JC, Boone EJ, et al. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J Biol Stand. 1983 Apr;11(2):91–97.
   PubMedGoogle Scholar
• WHO. Manual of laboratory methods for testing of vaccines used in the WHO Expanded Programme on Immunization: titration of human sera for neutralizing antibodies to poliovirus. WHO/VSQ/97.04 Geneva1997, p65–71. Available from: http://apps.who.int/iris/bitstream/handle/10665/63576/WHO_VSQ_97.04_(parts1-2).pdf?sequence=1. Accessed 4 May 2022.
   Google Scholar
• Chotpitayasunondh T, Thisyakorn U, Pancharoen C, et al. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age. Southeast Asian J Trop Med Public Health. 2012 Mar;43(2):442–454.
   PubMed Web of Science ®Google Scholar
• King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J. 1994 May;13(5):394–407.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Smith PJ, Hill HA. Evaluation of potentially achievable vaccination coverage with simultaneous administration of vaccines among children in the United States. Vaccine. 2016 Jun 8; 34(27):3030–3036.
   PubMed Web of Science ®Google Scholar
• Mosley JF 2nd, Smith LL, Parke CK, et al. Quadracel: vaccination against diphtheria, tetanus, pertussis, and poliomyelitis in children. P & T. 2016Apr; 414: 238–253.
   PubMedGoogle Scholar
• Study Group MMR. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Hum Vaccin Immunother. 2019;15(4):786–799.
   PubMed Web of Science ®Google Scholar
• Klein NP, Weston WM, Kuriyakose S, et al. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine. 2012 Jan 11 30(3):668–674.
   PubMed Web of Science ®Google Scholar
• Kang JH, Lee HJ, Kim KH, et al. The immunogenicity and safety of a combined DTaP-IPV//Hib vaccine compared with individual DTaP-IPV and Hib (PRP~T) vaccines: a randomized clinical trial in South Korean infants. J Korean Med Sci. 2016 Sep;31(9):1383–1391.
   PubMed Web of Science ®Google Scholar
• Lagos R, Kotloff K, Hoffenbach A, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J. 1998 Apr;17(4):294–304.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Borrow R, Da Costa X, et al. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vaccine. 2017 Jan 11 35(3):452–458.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Borrow R, Da Costa X, et al. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. Vaccine. 2018 Dec 18 36(52):8019–8027.
   PubMed Web of Science ®Google Scholar
• Aase A, Herstad TK, Jorgensen SB, et al. Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age. Vaccine. 2014 Oct 14 32(45):5931–5936.
   PubMed Web of Science ®Google Scholar
• Norwegian Surveillance System for Communicable Diseases (MSIS). Available from: http://www.msis.no/. Accessed 4 May 2022.
   Google Scholar
• Finnish Institute for Health and Welfare. Infectious diseases and vaccinations: dTaP-IPV vaccine for children (4-in-1). Available from: https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/diphtheria-tetanus-whooping-cough-polio-and-hib-combination-vaccines/dtap-ipv-vaccine-for-children-4-in-1-. Accessed 4 May 2022.
   Google Scholar
• Rapola S. National immunization program in Finland. Int J Circumpolar Health. 2007 Dec;66(5):382–389.
   PubMed Web of Science ®Google Scholar
• The Public Health Agency of Sweden. Evaluation of immunogenicity and effectiveness of low dose dTap-IPV vaccine used as booster in 4-8 year old children: a rapid literature review. Available from: https://www.folkhalsomyndigheten.se/contentassets/61c155f8099646ccb2d9b80dfde820c6/evaluation-tap-ipv-vaccine-01192-2017.pdf. Accessed 4 May 2022.
   Google Scholar
• Elomaa A, He Q, Minh NN, et al. Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine. 2009 Sep 4 27(40):5443–5449.
   PubMed Web of Science ®Google Scholar
• The Public Health Agency of Sweden. Pertussis surveillance in Sweden: 22nd annual report. Available from: https://www.folkhalsomyndigheten.se/contentassets/3ddd2fc3d4e94b56a31c2372777e2552/pertussis-surveillance-sweden-twenty-second-annual-report.pdf. Accessed 4 May 2022.
   Google Scholar
• Olin P, Hallander HO. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. Eurosurveillance. 1999 Dec;4(12):128–129.
   Google Scholar
• Voysey M, Kandasamy R, Yu LM, et al. The predicted persistence and kinetics of antibody decline 9 years after pre-school booster vaccination in UK children. Vaccine. 2016 Jul 29 34(35):4221–4228.
   PubMed Web of Science ®Google Scholar
• Zepp F, Habermehl P, Knuf M, et al. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine. 2007 Jul 20 25(29):5248–5252.
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Statement on the booster for 4-6 year-olds for protection against pertussis. Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/healthy-living/statement-booster-4-6-year-olds-protection-against-pertussis-advisory-committee-statement-national-advisory-committee-immunization-naci/pertussis-booster-2014-coqueluche-rappel-eng.pdf. Accessed 4 May 2022.
   Google Scholar
• Gabutti G, Trucchi C, Conversano M, et al. Booster vaccination: the role of reduced antigen content vaccines as a preschool booster. Biomed Res Int. 2014;2014:541319.
   PubMed Web of Science ®Google Scholar
• Marchal C, Belhassen M, Guiso N, et al. Vaccination coverage rates for Diphtheria, Tetanus. Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data. Vaccine. 2021 Jan 15;39(3):505–511.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012 Sep 13 367(11):1012–1019.
   PubMed Web of Science ®Google Scholar
• McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics. 2015 Feb;135(2):331–343.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Heininger U, Thomson A, et al. Controlling pertussis: how can we do it? A focus on immunization. Expert Rev Vaccines. 2018 Apr;17(4):289–297.
   PubMed Web of Science ®Google Scholar
• Hozbor D. New pertussis vaccines: a need and a challenge. Adv Exp Med Biol. 2019;1183:115–126.
   PubMed Web of Science ®Google Scholar
• Poolman JT. Shortcomings of pertussis vaccines: why we need a third generation vaccine. Expert Rev Vaccines. 2014 Oct;13(10):1159–1162.
   PubMed Web of Science ®Google Scholar
• Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. Curr Opin Immunol. 2019 Aug;59:72–78.
   PubMed Web of Science ®Google Scholar
• Macina D, Evans KE Bordetella pertussis in School-Age Children, Adolescents and Adults: a Systematic Review of Epidemiology and Mortality in Europe. Infect Dis Ther. 2021 Dec;10(4):2071–2118. doi:10.1007/s40121-021-00520-9.
   PubMed Web of Science ®Google Scholar
• Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in Asia. Infect Dis Ther. 2021 Sep;10(3):1115–1140.
   PubMed Web of Science ®Google Scholar
• Macina D, Evans KE. Bordetella pertussis in School-age children, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in the Middle East. Infect Dis Ther. 2021 Jun;10(2):719–738.
   PubMed Web of Science ®Google Scholar
• Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in Africa. Infect Dis Ther. 2021 Sep;10(3):1097–1113.
   PubMed Web of Science ®Google Scholar
• Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics. 2000 Jan;105(1):e12.
   PubMed Web of Science ®Google Scholar
• Southern J, Waight PA, Andrews N, et al. Extensive swelling of the limb and systemic symptoms after a fourth dose of acellular pertussis containing vaccines in England in children aged 3-6years. Vaccine. 2017 Jan 23 35(4):619–625.
   PubMed Web of Science ®Google Scholar
• Woo EJ, Burwen DR, Gatumu SN, et al. Extensive limb swelling after immunization: reports to the vaccine adverse event reporting system. Clinl Infect Dis. 2003 Aug 1 37(3):351–358.
   PubMed Web of Science ®Google Scholar
• Daley MF, Yih WK, Glanz JM, et al. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine. Vaccine. 2014 May 23 32(25):3019–3024.
   PubMed Web of Science ®Google Scholar
• Lee SM, Kim SJ, Chen J, et al. Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children. Hum Vaccin Immunother. 2019;15(5):1145–1153.
   PubMed Web of Science ®Google Scholar
• Langley JM, Predy G, Guasparini R, et al. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine. 2007 Jan 22 25(6):1121–1125.
   PubMed Web of Science ®Google Scholar
• Rowe J, Yerkovich ST, Richmond P, et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun. 2005 Dec;73(12):8130–8135.
   PubMed Web of Science ®Google Scholar
• Muhoza P, Danovaro-Holliday MC, Diallo MS, et al. Routine vaccination coverage - worldwide. Morbidity Mortality Weekly Rep. 2020 [2021 Oct 29];70(43):1495–1500.
   Web of Science ®Google Scholar